Outcomes of gynecologic cancer surgery during the COVID-19 pandemic: an international, multicenter, prospective CovidSurg-Gynecologic Oncology Cancer study

Mental distress, quality of life and physical symptoms in Chinese women with ovarian cancer receiving olaparib treatment during the COVID-19 pandemic

“…In a recent study on general OC patients conducted in the United States, 33% OC patients experienced a delay in some component of their cancer care among which 26.3% scheduled for surgery and only 8.3% scheduled for nonsurgical treatment experienced a delay ( 10 ). Another study observed a surgery delay in 15.7% of patients with ovarian cancer, which was associated with disease progression and death ( 37 ). This disparity might be attributed to the study populations in terms of a previous study observed an association between delay in oncology care and anxiety or depression among OC patients ( 10 ), while in our study, similar associations were not found, but we found delay in cancer care was significantly related to insomnia symptom.…”

Cancer surgery during COVID increased the patient mortality and the transmission risk to healthcare workers: results from a retrospective cohort study (NCT05240378)

“…A higher risk of mortality after surgery was shown in hospitals with more than 25% of patients with COVID-19 [ 16 ], while others have reported no increase in mortality [ 17 ]. Most studies reporting worst outcome reported late presentation or delay as the cause of increased mortality [ 18 , 19 ]. The presence of perioperative COVID-19 has also been found to be associated with higher mortality and morbidity [ 20 ].…”

The evolving impact of COVID‐19 on women's health

“…Cancelled theatre lists and reduced high dependency unit capacity meant that as many as one in five women with gynaecological cancer received modifications to their treatment that rendered their management suboptimal. 2 The combined impact of these factors on long term patient outcomes is yet to be fully realised.…”